Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
live double combined lactobacillus
- Development stage
- Phase 4
- Lead developer
- 广东龙创基药业
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Vaginal
01
Overview
Live double combined lactobacillus is a vaginal live biotherapeutic product (LBP) being developed by Guangdong Longchuangji Pharmaceutical for the treatment of bacterial vaginosis (BV). The formulation consists of two specific strains of live Lactobacillus bacteria delivered via a vaginal capsule. Its mechanism of action involves the restoration of the normal vaginal microflora, which is typically dominated by lactobacilli in healthy women. By colonizing the vaginal epithelium, these bacteria produce lactic acid to maintain an acidic pH and generate antimicrobial substances like hydrogen peroxide, thereby inhibiting the overgrowth of anaerobic pathogens such as Gardnerella vaginalis associated with BV.
- Other names
- live double combined lactobacillus capsule (vaginal)阴道用活双联合乳杆菌胶囊
02
Targets
BVAB (Bacterial vaginosis-associated bacteria)PRR (Pattern recognition receptors)
Beyond the preview
Go deeper on live double combined lactobacillus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on live double combined lactobacillus.